Clinical Trial

A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma

Name: A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma — clinical trial record (NCT07710690)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The primary objective of this study is to determine the safe dose range of NRG-103 in patients and to recommend the dosage for subsequent treatment, while also evaluating the preliminary efficacy and tolerability of the product.

Trial Details

NCT Number	NCT07710690
Lead Sponsor	Neuregen Therapeutics Co., Ltd.
Conditions	HGG, High Grade Glioma (III or IV), High Grade Glioma
Enrollment	24 participants
Start Date	2026-07-09
Primary Completion	2030-04-30 (estimated)
Study Completion	2030-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-17